Hydroxyurea is associated with lower prevalence of albuminuria in adults with sickle cell disease

Louis Philippe Laurin, Patrick H. Nachman, Payal C. Desai, Kenneth Ataga, Vimal K. Derebail

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Background. Albuminuria is an early manifestation of sickle cell nephropathy. Prior small case series suggests benefit of hydroxyurea in reducing albuminuria, with a similar trend noted in pediatric studies. We aimed to comprehensively evaluate hydroxyurea use and prevalence of albuminuria in adult sickle cell patients. Methods. We performed a cross-sectional study of 149 adult patients followed between 2000 and 2011 in a comprehensive sickle cell clinic. All patients were assessed for albuminuria either by direct measurement or by urinary chemical strip (dipstick) testing. Urinary albumin-to-creatinine ratios (UACRs) were available for 112 patients. Hydroxyurea exposure was defined as ≥3 months of therapy before the assessment of albuminuria. Albuminuria was defined as either UACR ≥30 mg/g or ≥1+ proteinuria on two separate dipsticks. We constructed a multivariate logistic regression model to assess the association between hydroxyurea and albuminuria. Results. The prevalence of albuminuria was lower among patients on hydroxyurea (34.7 versus 55.4%; P = 0.01) as was median albumin excretion (17.9 versus 40.5 mg/g; P = 0.04). In multivariate analysis, hydroxyurea was associated with a lower likelihood of albuminuria (odds ratio 0.28, 95% CI: 0.11-0.75, P = 0.01), adjusting for age, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use, tricuspid regurgitant jet velocity, hypertension and acute chest syndrome. Conclusions. In our population of sickle cell patients, those using hydroxyurea were less than one-third as likely to exhibit albuminuria. Hydroxyurea use may prevent development of overt nephropathy or the progression of sickle cell disease nephropathy to end-stage renal disease, and its use for this indication merits further investigation.

Original languageEnglish (US)
Pages (from-to)1211-1218
Number of pages8
JournalNephrology Dialysis Transplantation
Volume29
Issue number6
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Albuminuria
Hydroxyurea
Sickle Cell Anemia
Albumins
Creatinine
Acute Chest Syndrome
Logistic Models
Angiotensin Receptor Antagonists
Proteinuria
Angiotensin-Converting Enzyme Inhibitors
Chronic Kidney Failure
Multivariate Analysis
Cross-Sectional Studies
Odds Ratio
Pediatrics
Hypertension

All Science Journal Classification (ASJC) codes

  • Nephrology
  • Transplantation

Cite this

Hydroxyurea is associated with lower prevalence of albuminuria in adults with sickle cell disease. / Laurin, Louis Philippe; Nachman, Patrick H.; Desai, Payal C.; Ataga, Kenneth; Derebail, Vimal K.

In: Nephrology Dialysis Transplantation, Vol. 29, No. 6, 01.01.2014, p. 1211-1218.

Research output: Contribution to journalArticle

Laurin, Louis Philippe ; Nachman, Patrick H. ; Desai, Payal C. ; Ataga, Kenneth ; Derebail, Vimal K. / Hydroxyurea is associated with lower prevalence of albuminuria in adults with sickle cell disease. In: Nephrology Dialysis Transplantation. 2014 ; Vol. 29, No. 6. pp. 1211-1218.
@article{61da1082731f4701bad9a87112817aa1,
title = "Hydroxyurea is associated with lower prevalence of albuminuria in adults with sickle cell disease",
abstract = "Background. Albuminuria is an early manifestation of sickle cell nephropathy. Prior small case series suggests benefit of hydroxyurea in reducing albuminuria, with a similar trend noted in pediatric studies. We aimed to comprehensively evaluate hydroxyurea use and prevalence of albuminuria in adult sickle cell patients. Methods. We performed a cross-sectional study of 149 adult patients followed between 2000 and 2011 in a comprehensive sickle cell clinic. All patients were assessed for albuminuria either by direct measurement or by urinary chemical strip (dipstick) testing. Urinary albumin-to-creatinine ratios (UACRs) were available for 112 patients. Hydroxyurea exposure was defined as ≥3 months of therapy before the assessment of albuminuria. Albuminuria was defined as either UACR ≥30 mg/g or ≥1+ proteinuria on two separate dipsticks. We constructed a multivariate logistic regression model to assess the association between hydroxyurea and albuminuria. Results. The prevalence of albuminuria was lower among patients on hydroxyurea (34.7 versus 55.4{\%}; P = 0.01) as was median albumin excretion (17.9 versus 40.5 mg/g; P = 0.04). In multivariate analysis, hydroxyurea was associated with a lower likelihood of albuminuria (odds ratio 0.28, 95{\%} CI: 0.11-0.75, P = 0.01), adjusting for age, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use, tricuspid regurgitant jet velocity, hypertension and acute chest syndrome. Conclusions. In our population of sickle cell patients, those using hydroxyurea were less than one-third as likely to exhibit albuminuria. Hydroxyurea use may prevent development of overt nephropathy or the progression of sickle cell disease nephropathy to end-stage renal disease, and its use for this indication merits further investigation.",
author = "Laurin, {Louis Philippe} and Nachman, {Patrick H.} and Desai, {Payal C.} and Kenneth Ataga and Derebail, {Vimal K.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1093/ndt/gft295",
language = "English (US)",
volume = "29",
pages = "1211--1218",
journal = "Nephrology Dialysis Transplantation",
issn = "0931-0509",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Hydroxyurea is associated with lower prevalence of albuminuria in adults with sickle cell disease

AU - Laurin, Louis Philippe

AU - Nachman, Patrick H.

AU - Desai, Payal C.

AU - Ataga, Kenneth

AU - Derebail, Vimal K.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background. Albuminuria is an early manifestation of sickle cell nephropathy. Prior small case series suggests benefit of hydroxyurea in reducing albuminuria, with a similar trend noted in pediatric studies. We aimed to comprehensively evaluate hydroxyurea use and prevalence of albuminuria in adult sickle cell patients. Methods. We performed a cross-sectional study of 149 adult patients followed between 2000 and 2011 in a comprehensive sickle cell clinic. All patients were assessed for albuminuria either by direct measurement or by urinary chemical strip (dipstick) testing. Urinary albumin-to-creatinine ratios (UACRs) were available for 112 patients. Hydroxyurea exposure was defined as ≥3 months of therapy before the assessment of albuminuria. Albuminuria was defined as either UACR ≥30 mg/g or ≥1+ proteinuria on two separate dipsticks. We constructed a multivariate logistic regression model to assess the association between hydroxyurea and albuminuria. Results. The prevalence of albuminuria was lower among patients on hydroxyurea (34.7 versus 55.4%; P = 0.01) as was median albumin excretion (17.9 versus 40.5 mg/g; P = 0.04). In multivariate analysis, hydroxyurea was associated with a lower likelihood of albuminuria (odds ratio 0.28, 95% CI: 0.11-0.75, P = 0.01), adjusting for age, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use, tricuspid regurgitant jet velocity, hypertension and acute chest syndrome. Conclusions. In our population of sickle cell patients, those using hydroxyurea were less than one-third as likely to exhibit albuminuria. Hydroxyurea use may prevent development of overt nephropathy or the progression of sickle cell disease nephropathy to end-stage renal disease, and its use for this indication merits further investigation.

AB - Background. Albuminuria is an early manifestation of sickle cell nephropathy. Prior small case series suggests benefit of hydroxyurea in reducing albuminuria, with a similar trend noted in pediatric studies. We aimed to comprehensively evaluate hydroxyurea use and prevalence of albuminuria in adult sickle cell patients. Methods. We performed a cross-sectional study of 149 adult patients followed between 2000 and 2011 in a comprehensive sickle cell clinic. All patients were assessed for albuminuria either by direct measurement or by urinary chemical strip (dipstick) testing. Urinary albumin-to-creatinine ratios (UACRs) were available for 112 patients. Hydroxyurea exposure was defined as ≥3 months of therapy before the assessment of albuminuria. Albuminuria was defined as either UACR ≥30 mg/g or ≥1+ proteinuria on two separate dipsticks. We constructed a multivariate logistic regression model to assess the association between hydroxyurea and albuminuria. Results. The prevalence of albuminuria was lower among patients on hydroxyurea (34.7 versus 55.4%; P = 0.01) as was median albumin excretion (17.9 versus 40.5 mg/g; P = 0.04). In multivariate analysis, hydroxyurea was associated with a lower likelihood of albuminuria (odds ratio 0.28, 95% CI: 0.11-0.75, P = 0.01), adjusting for age, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use, tricuspid regurgitant jet velocity, hypertension and acute chest syndrome. Conclusions. In our population of sickle cell patients, those using hydroxyurea were less than one-third as likely to exhibit albuminuria. Hydroxyurea use may prevent development of overt nephropathy or the progression of sickle cell disease nephropathy to end-stage renal disease, and its use for this indication merits further investigation.

UR - http://www.scopus.com/inward/record.url?scp=84901812596&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901812596&partnerID=8YFLogxK

U2 - 10.1093/ndt/gft295

DO - 10.1093/ndt/gft295

M3 - Article

VL - 29

SP - 1211

EP - 1218

JO - Nephrology Dialysis Transplantation

JF - Nephrology Dialysis Transplantation

SN - 0931-0509

IS - 6

ER -